The rate of all cause mortality was actually lower in the Exubera group. That is good news. However.....

I've been out of cancer for a few years now but I had a few thoughts..in lung cancer, median survival is all about catching the disease when treatment can still be effective. Most lung cancers are caught when they are symptomatic, which is usually Stage 4 and treatments, despite a lot of new approaches, are marginal extending survival by months at best.

If they are screening these patients, are they catching the disease early in Stage 1 and Stage 2? They then can treat and extend survival to 3-5 years? Have many of these patients not died yet? I read the abstract once but don't remember the time frame to which this study is measuring. It is possible the data could get worse.

Even if Afrezza is different, we will need a LOT of our own data to not throw the baby out with the bathwater. I'm holding my position but not adding more as I have been tempted to with the price drop.